Avanos Medical (AVNS) EBIT (2013 - 2026)

Avanos Medical has disclosed EBIT across 14 years of filings, most recently posting $8.9 million for Q1 2026.

• In Q1 2026, EBIT fell 13.59% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at -$63.0 million (up 83.84% YoY), while the FY2025 annual figure was -$61.6 million, up 84.45% from the prior year.
• EBIT came in at $8.9 million for Q1 2026 at Avanos Medical, up from $2.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $16.6 million in Q4 2022 to a low of -$418.5 million in Q4 2024.
• Average EBIT over 5 years is -$23.3 million, with a median of $6.3 million recorded in 2024.
• The largest YoY upside for EBIT was 900.0% in 2024 against a maximum downside of 3836.61% in 2024.
• Over 5 years, EBIT stood at $16.6 million in 2022, then sank by 32.53% to $11.2 million in 2023, then tumbled by 3836.61% to -$418.5 million in 2024, then jumped by 100.6% to $2.5 million in 2025, then soared by 256.0% to $8.9 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $8.9 million in Q1 2026, $2.5 million in Q4 2025, and $100000.0 in Q3 2025.